Epstein-Barr Virus Evades CD4 T Cell Responses in Lytic Cycle through BZLF1-mediated Downregulation of CD74 and the Cooperation of vBcl-2

English version České info

Evasion of immune T cell responses is crucial for viruses to establish persistence in the infected host. Immune evasion mechanisms of Epstein-Barr virus (EBV) in the context of MHC-I antigen presentation have been well studied. In contrast, viral interference with MHC-II antigen presentation is less well understood, not only for EBV but also for other persistent viruses. Here we show that the EBV encoded BZLF1 can interfere with recognition by immune CD4⁺ effector T cells. This impaired T cell recognition occurred in the absence of a reduction in the expression of surface MHC-II, but correlated with a marked downregulation of surface CD74 on the target cells. Furthermore, impaired CD4⁺ T cell recognition was also observed with target cells where CD74 expression was downregulated by shRNA-mediated inhibition. BZLF1 downregulated surface CD74 via a post-transcriptional mechanism distinct from its previously reported effect on the CIITA promoter. In addition to being a chaperone for MHC-II αβ dimers, CD74 also functions as a surface receptor for macrophage Migration Inhibitory Factor and enhances cell survival through transcriptional upregulation of Bcl-2 family members. The immune-evasion function of BZLF1 therefore comes at a cost of induced toxicity. However, during EBV lytic cycle induced by BZLF1 expression, this toxicity can be overcome by expression of the vBcl-2, BHRF1, at an early stage of lytic infection. We conclude that by inhibiting apoptosis, the vBcl-2 not only maintains cell viability to allow sufficient time for synthesis and accumulation of infectious virus progeny, but also enables BZLF1 to effect its immune evasion function.

Vyšlo v časopise: Epstein-Barr Virus Evades CD4 T Cell Responses in Lytic Cycle through BZLF1-mediated Downregulation of CD74 and the Cooperation of vBcl-2. PLoS Pathog 7(12): e32767. doi:10.1371/journal.ppat.1002455
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1002455

Souhrn

Zdroje

1. RickinsonABKieffE 2007 Epstein-Barr virus. KnipeDMHowleyPM Fields Virology Philadelphia Walters Kluwer/Lippincott, Williams & Wilkins 2655 2700

2. RoweMGlaunsingerBvan LeeuwenDZuoJSweetmanD 2007 Host shutoff during productive Epstein-Barr virus infection is mediated by BGLF5 and may contribute to immune evasion. Proc Natl Acad Sci U S A 104 3366 3371

3. ZuoJThomasWvan LeeuwenDMiddeldorpJMWiertzEJ 2008 The DNase of gammaherpesviruses impairs recognition by virus-specific CD8+ T cells through an additional host shutoff function. J Virol 82 2385 2393

4. HislopADRessingMEvan LeeuwenDPudneyVAHorstD 2007 A CD8+ T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates. J Exp Med 204 1863 1873

5. ZuoJCurrinAGriffinBDShannon-LoweCThomasWA 2009 The Epstein-Barr virus G-protein-coupled receptor contributes to immune evasion by targeting MHC class I molecules for degradation. PLoS Pathog 5 e1000255

6. ZuoJQuinnLLTamblynJThomasWAFeederleR 2011 The Epstein-Barr Virus-Encoded BILF1 Protein Modulates Immune Recognition of Endogenously Processed Antigen by Targeting Major Histocompatibility Complex Class I Molecules Trafficking on both the Exocytic and Endocytic Pathways. J Virol 85 1604 1614

7. ZeidlerREissnerGMeissnerPUebelSTampeR 1997 Downregulation of TAP1 in B Lymphocytes by Cellular and Epstein-Barr Virus-Encoded Interleukin-10. Blood 90 2390 2397

8. LongHMHaighTAGudgeonNHLeenAMTsangC-W 2005 CD4+ T-Cell Responses to Epstein-Barr Virus (EBV) Latent-Cycle Antigens and the Recognition of EBV-Transformed Lymphoblastoid Cell Lines. J Virol 79 4896 4907

9. AdhikaryDBehrendsUMoosmannAWitterKBornkammGW 2006 Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins. J Exp Med 203 995 1006

10. LongHMLeeseAMChagouryOLConnertySRQuarcoopomeJ 2011 Cytotoxic CD4+ T Cell Responses to EBV Contrast with CD8 Responses in Breadth of Lytic Cycle Antigen Choice and in Lytic Cycle Recognition. J Immunol 187 92 101

11. TomazinRBonameJHegdeNRLewinsohnDMAltschulerY 1999 Cytomegalovirus US2 destroys two components of the MHC class II pathway, preventing recognition by CD4+ T cells. Nat Med 5 1039 1043

12. HegdeNRTomazinRAWisnerTWDunnCBonameJM 2002 Inhibition of HLA-DR Assembly, Transport, and Loading by Human Cytomegalovirus Glycoprotein US3: a Novel Mechanism for Evading Major Histocompatibility Complex Class II Antigen Presentation. J Virol 76 10929 10941

13. OdebergJPlachterBBrandenLSoderberg-NauclerC 2003 Human cytomegalovirus protein pp65 mediates accumulation of HLA-DR in lysosomes and destruction of the HLA-DR α-chain. Blood 101 4870 4877

14. TemmeSEis-HübingerAMMcLellanADKochN 2010 The Herpes Simplex Virus-1 Encoded Glycoprotein B Diverts HLA-DR into the Exosome Pathway. J Immunol 184 236 243

15. RessingMEvan LeeuwenDVerreckFAWGomezRHeemskerkB 2003 Interference with T cell receptor-HLA-DR interactions by Epstein-Barr virus gp42 results in reduced T helper cell recognition. Proc Natl Acad Sci U S A 100 11583 11588

16. RessingMEvan LeeuwenDVerreckFAWKeatingSGomezR 2005 Epstein-Barr Virus gp42 Is Posttranslationally Modified To Produce Soluble gp42 That Mediates HLA Class II Immune Evasion. J Virol 79 841 852

17. LiDQianLChenCShiMYuM 2009 Down-Regulation of MHC Class II Expression through Inhibition of CIITA Transcription by Lytic Transactivator Zta during Epstein-Barr Virus Reactivation. J Immunol 182 1799 1809

18. PaludanCSchmidDLandthalerMVockerodtMKubeD 2005 Endogenous MHC Class II Processing of a Viral Nuclear Antigen After Autophagy. Science 307 593 596

19. ZhouDLiPLinYLottJMHislopAD 2005 Lamp-2a Facilitates MHC Class II Presentation of Cytoplasmic Antigens. Immunity 22 571 581

20. LeungCSHaighTAMackayLKRickinsonABTaylorGS 2010 Nuclear location of an endogenously expressed antigen, EBNA1, restricts access to macroautophagy and the range of CD4 epitope display. Proc Natl Acad Sci U S A 107 2165 2170

21. HendersonSHuenDRoweMDawsonCJohnsonG 1993 Epstein-Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death. Proc Natl Acad Sci U S A 90 8479 8483

22. ChangCHFlavellRA 1995 Class II transactivator regulates the expression of multiple genes involved in antigen presentation. J Exp Med 181 765 767

23. RochaNNeefjesJ 2008 MHC class II molecules on the move for successful antigen presentation. EMBO J 27 1 5

24. van den HoornTPaulPJongsmaMLMNeefjesJ 2011 Routes to manipulate MHC class II antigen presentation. Curr Opin Immunol 23 88 95

25. RochePATeletskiCLStangEBakkeOLongEO 1993 Cell surface HLA-DR-invariant chain complexes are targeted to endosomes by rapid internalization. Proc Natl Acad Sci U S A 90 8581 8585

26. StarletsDGoreYBinskyIHaranMHarpazN 2006 Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival. Blood 107 4807 4816

27. LantnerFStarletsDGoreYFlaishonLYamit-HeziA 2007 CD74 induces TAp63 expression leading to B-cell survival. Blood 110 4303 4311

28. ZhuLJonesPP 1990 Transcriptional control of the invariant chain gene involves promoter and enhancer elements common to and distinct from major histocompatibility complex class II genes. Mol Cell Biol 10 3906 3916

29. RessingMEKeatingSEvan LeeuwenDKoppers-LalicDPappworthIY 2005 Impaired Transporter Associated with Antigen Processing-Dependent Peptide Transport during Productive EBV Infection. J Immunol 174 6829 6838

30. RomagnoliPGermainRN 1994 The CLIP region of invariant chain plays a critical role in regulating major histocompatibility complex class II folding, transport, and peptide occupancy. J Exp Med 180 1107 1113

31. MoldenhauerHenneKarhausenMÖLler 1999 Surface-expressed invariant chain (CD74) is required for internalization of human leucocyte antigen-DR molecules to early endosomal compartments. Immunology 96 473 484

32. OngGoldenbergHansenMattes 1999 Cell surface expression and metabolism of major histocompatibility complex class II invariant chain (CD74) by diverse cell lines. Immunology 98 296 302

33. ShacharIFlavellRA 1996 Requirement for Invariant Chain in B Cell Maturation and Function. Science 274 106 108

34. MatzaDWolsteinODiksteinRShacharI 2001 Invariant Chain Induces B Cell Maturation by Activating a TAFII105-NF-kB-dependent Transcription Program. J Biol Chem 276 27203 27206

35. MatzaDLantnerFBogochYFlaishonLHershkovizR 2002 Invariant chain induces B cell maturation in a process that is independent of its chaperonic activity. Proc Natl Acad Sci U S A 99 3018 3023

36. SteinRQuZCardilloTMChenSRosarioA 2004 Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies. Blood 104 3705 3711

37. MorrisonTEKenneySC 2004 BZLF1, an Epstein-Barr virus immediate-early protein, induces p65 nuclear translocation while inhibiting p65 transcriptional function. Virology 328 219 232

38. KvansakulMWeiAHFletcherJIWillisSNChenL 2010 Structural Basis for Apoptosis Inhibition by Epstein-Barr Virus BHRF1. PLoS Pathog 6 e1001236

39. MarshallWLYimCGustafsonEGrafTSageDR 1999 Epstein-Barr Virus Encodes a Novel Homolog of the bcl-2 Oncogene That Inhibits Apoptosis and Associates with Bax and Bak. J Virol 73 5181 5185

40. MorrisonTEMauserAWongATingJPKenneySC 2001 Inhibition of IFN-gamma signaling by an Epstein-Barr virus immediate-early protein. Immunity 15 787 799

41. MorrisonTEMauserAKlingelhutzAKenneySC 2004 Epstein-Barr virus immediate-early protein BZLF1 inhibits tumor necrosis factor alpha-induced signaling and apoptosis by downregulating tumor necrosis factor receptor 1. J Virol 78 544 549

42. BristolJARobinsonARBarlowEAKenneySC 2010 The Epstein-Barr virus BZLF1 protein inhibits tumor necrosis factor receptor 1 expression through effects on cellular C/EBP proteins. J Virol 84 12362 12374

43. RoweMZuoJ 2010 Immune responses to Epstein-Barr virus: molecular interactions in the virus evasion of CD8+ T cell immunity. Microbes Infect 12 173 181

44. KellyGLLongHMStylianouJThomasWALeeseA 2009 An Epstein-Barr Virus Anti-Apoptotic Protein Constitutively Expressed in Transformed Cells and Implicated in Burkitt Lymphomagenesis: The Wp/BHRF1 Link. PLoS Pathog 5 e1000341

45. FeederleRKostMBaumannMJanzADrouetE 2000 The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators. EMBO J 19 3080 3089

46. JohnsonJPDemmer-DieckmannMMeoTHadamMRRiethmüllerG 1981 Surface antigens of human melanoma cells defined by monoclonal antibodies. I. Biochemical characterization of two antigens found on cell lines and fresh tumors of diverse tissue origin. Eur J Immunol 11 825 831

47. PezzellaFTseAGCordellJLPulfordKAGatterKC 1990 Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation. Am J Pathol 137 8

48. CroftNPShannon-LoweCBellAIHorstDlKremmerE 2009 Stage-Specific Inhibition of MHC Class I Presentation by the Epstein-Barr Virus BNLF2a Protein during Virus Lytic Cycle. PLoS Pathog 5 e1000490

49. BlakeNLeeSRedchenkoIThomasWStevenN 1997 Human CD8+ T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing. Immunity 7 791 802